Affimed (NASDAQ:AFMD) Receives Consensus Rating of “Buy” from Analysts

Shares of Affimed (NASDAQ:AFMD) have been given an average recommendation of “Buy” by the five ratings firms that are currently covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have covered the stock in the last year is $45.00.

AFMD has been the subject of several recent analyst reports. Wells Fargo & Company reduced their price objective on shares of Affimed from $30.00 to $25.00 and set an “overweight” rating for the company in a research note on Monday, April 1st. HC Wainwright lifted their price objective on Affimed to $10.00 and gave the company a “buy” rating in a research note on Monday, April 1st. StockNews.com initiated coverage on Affimed in a report on Tuesday, January 2nd. They issued a “sell” rating on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Affimed in a report on Monday, April 1st.

Affimed Stock Down 4.4 %

Shares of NASDAQ AFMD opened at $5.83 on Thursday. The business has a 50-day simple moving average of $5.55 and a two-hundred day simple moving average of $4.97. Affimed has a 52 week low of $2.23 and a 52 week high of $11.10. The company has a market cap of $88.77 million, a P/E ratio of -0.69 and a beta of 2.05. The company has a quick ratio of 3.23, a current ratio of 3.25 and a debt-to-equity ratio of 0.11.

Hedge Funds Weigh In On Affimed

Hedge funds and other institutional investors have recently modified their holdings of the company. Vestal Point Capital LP purchased a new position in shares of Affimed during the 4th quarter valued at about $341,000. BNP Paribas Financial Markets lifted its holdings in shares of Affimed by 39.9% in the 4th quarter. BNP Paribas Financial Markets now owns 571,975 shares of the biopharmaceutical company’s stock worth $357,000 after acquiring an additional 163,162 shares during the last quarter. EWA LLC bought a new stake in shares of Affimed in the 4th quarter worth approximately $89,000. abrdn plc bought a new position in shares of Affimed during the 4th quarter valued at $130,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in Affimed in the 2nd quarter worth $129,000. 30.82% of the stock is currently owned by hedge funds and other institutional investors.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.